Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 158.4% in December

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 603,238 shares, an increase of 158.4% from the December 15th total of 233,417 shares. Based on an average daily volume of 573,162 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.3% of the shares of the stock are sold short. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily volume of 573,162 shares, the days-to-cover ratio is currently 1.1 days.

More Enlivex Therapeutics News

Here are the key news stories impacting Enlivex Therapeutics this week:

• Positive Sentiment: Price-target boost — a published note reports ENLV’s price target was raised ~85.7% to $13.26, a headline-driving upgrade that can attract buyers and speculative interest. Price Target Increase
• Positive Sentiment: HC Wainwright research update — the firm maintains a “Buy” rating with a $13 price objective and published quarterly and FY2026 EPS estimates (Q1–Q4 2026: about ($0.01) each; FY2026: ($0.05)), implying materially narrower losses than the street consensus (~($0.70) FY). That upward revision in expectations is the underlying driver of the target move and supports upside sentiment. HC Wainwright Note
• Negative Sentiment: Company remains unprofitable and high-risk — despite improved forecasts, analysts still model negative EPS for 2025–2026 and Enlivex remains exposed to typical biotech risks (clinical, regulatory, financing). That ongoing uncertainty can cap valuation and keep shares volatile. Analyst Consensus Details

Institutional Investors Weigh In On Enlivex Therapeutics

Several institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP purchased a new position in Enlivex Therapeutics in the third quarter valued at $57,000. Citizens Financial Group Inc. RI acquired a new position in shares of Enlivex Therapeutics during the 3rd quarter worth about $241,000. Finally, Jane Street Group LLC raised its position in shares of Enlivex Therapeutics by 527.4% during the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after acquiring an additional 67,886 shares in the last quarter. 1.02% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a research note on Monday, December 29th. HC Wainwright lifted their target price on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday. D Boral Capital cut shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Wall Street Zen downgraded Enlivex Therapeutics to a “strong sell” rating in a research report on Saturday, December 27th. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of Enlivex Therapeutics in a research note on Monday, November 24th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $13.00.

Enlivex Therapeutics Trading Up 4.6%

ENLV traded up $0.04 during trading hours on Thursday, hitting $1.01. 473,553 shares of the company’s stock were exchanged, compared to its average volume of 399,226. The firm has a market cap of $239.99 million, a P/E ratio of -1.86 and a beta of 1.52. Enlivex Therapeutics has a 12-month low of $0.66 and a 12-month high of $2.10. The firm has a 50 day moving average of $0.91 and a 200 day moving average of $1.08.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. As a group, research analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current fiscal year.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.